• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


All the latest conference updates; those that we are attending and the studies that we are presenting

Transpharmation's EEG experts Dr. John Huxter and Dr. Sandor Kantor discussed how EEG can bridge the gap between basic research, preclinical drug discovery and human clinical trials at a virtual social (SO39) at the SfN Connectome on Tuesday 12th January at 9-10am EST (2-3pm GMT). This social stimulated discussion around what EEG measures offer the best hope for predicting clinical outcomes, probing strengths, weaknesses, and usage of measures like ASSR and MMN.


Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design